TRAILR2/TNFRSF10B Antibody (drozitumab)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28785

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # drozitumab

Concentration

LYOPH mg/ml

View all TRAIL R2/TNFRSF10B Antibodies »

Product Specifications

Immunogen

TNFRSF10B / TRAILR2 / CD262

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.

Also known as 'drozitumab'.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Scientific Data Images for TRAILR2/TNFRSF10B Antibody (drozitumab)

TRAILR2/TNFRSF10B Antibody (drozitumab)

ELISA: TRAILR2/TNFRSF10B Antibody (drozitumab)[NBP3-28785] -

Immobilized Cynomolgus TRAIL R2/DR5/ TNFRSF10B Protein, His Tag at 2 ug/mL can bind drozitumab, EC50=0.1257 ug/mL.

Applications for TRAILR2/TNFRSF10B Antibody (drozitumab)

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: TRAIL R2/TNFRSF10B

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family. DR4 was recently identified as the receptor for TRAIL. A novel death domain containing receptor for TRAIL was more recently identified and designated DR5, Apo2, TRAIL-R2, TRICK2, or KILLER by several groups independently (1-2). Like DR4, DR5 transcript is widely expressed in normal tissues and in many types of tumor cells. DR5 binds to TRAIL and mediates TRAIL induced cell death. Overexpression of DR5 induces apoptosis and activates NF-kB.

Long Name

TRAIL Receptor 2

Alternate Names

CD262, DR5, TNFRSF10B, TRAILR2

Gene Symbol

TNFRSF10B

UniProt

O14763

Additional TRAIL R2/TNFRSF10B Products

Product Documents for TRAILR2/TNFRSF10B Antibody (drozitumab)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for TRAILR2/TNFRSF10B Antibody (drozitumab)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.